Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug;60(8):1161-71.
doi: 10.1007/s00262-011-1012-8. Epub 2011 Apr 6.

Camouflage and sabotage: tumor escape from the immune system

Isabel Poschke  1 , Dimitrios Mougiakakos, Rolf Kiessling
Affiliations
Review

Camouflage and sabotage: tumor escape from the immune system

Isabel Poschke et al. Cancer Immunol Immunother. 2011 Aug.

Abstract

The field of tumor immunology has made great progress in understanding tumor immune interactions. As a consequence a number of immuno-therapeutic approaches have been successfully introduced into the clinic and a large number of promising therapeutic strategies are investigated in ongoing clinical trials. Evaluation of anti-tumor immunity in such trials as well as in animal models has shown that tumor escape from immune recognition and tumor-mediated suppression of anti-tumor immunity can pose a significant obstacle to successful cancer therapy. Here, we review mechanisms of tumor immune escape and immune-subversion with a focus on the research interests in our laboratory: loss of MHC class I on tumor cells, increased oxidative stress, recruitment of myeloid-derived suppressor cells, and regulatory T cells.

PubMed Disclaimer

References

    1. Moller G, Moller E. Studies in vitro and in vivo of the cytotoxic and enhancing effect of humoral isoantibodies. Ann NY Acad Sci. 1962;99:504–530. doi: 10.1111/j.1749-6632.1962.tb45332.x. - DOI - PubMed
    1. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature reviews. 2009;9(7):463–475. - PubMed
    1. Eggermont AM, Testori A, Maio M, Robert C. Anti-CTLA-4 antibody adjuvant therapy in melanoma. Semin Oncol. 2010;37(5):455–459. doi: 10.1053/j.seminoncol.2010.09.009. - DOI - PubMed
    1. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175–208. doi: 10.1146/annurev.immunol.24.021605.090733. - DOI - PubMed
    1. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999;80(2):219–230. doi: 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S. - DOI - PubMed

Publication types

MeSH terms

Substances